Blue Shield of California February 2023 Standard/Value Drug Formulary Changes

Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies. Our Pharmacy and Therapeutics (P&T) Committee is made up of a group of practicing physicians and pharmacists who meet quarterly to recommend changes to our formulary based on the latest medical literature, new clinical guidelines, new information from key physician experts, and new information from the Food and Drug Administration.

Changes to the Standard/Value Drug Formulary from the February 2023 P&T Committee meeting are outlined below. To view a copy of the Standard/Value Drug Formulary, please download a copy.

The drugs listed below are to be used for FDA-approved indications but may also be used for other conditions.

1. DRUGS ADDED TO FORMULARY

The following drugs were added to the formulary:

Drug	FDA Indication(s)	Coverage Restriction(s)	Tier Status
elixophyllin 80mg/15ml elixir	Asthma, COPD		Tier 1
fingolimod (Gilenya)	Multiple sclerosis	Quantity limit	Tier 4
levofloxacin 1.5% eye drops	Corneal ulcer		Tier 1
roflumilast (Daliresp)	COPD	Prior authorization, Quantity limit	Tier 2

2. FORMULARY DRUGS WITH CHANGES TO TIER AND/OR COVERAGE RESTRICTION

The following drugs have coverage restriction(s) added or removed, and/or change of tier status as noted:

Drug	FDA Indication(s)	Coverage Restriction(s)	New Tier Status
aprepitant capsule (Emend)	Chemotherapy-induced nausea and vomiting	Remove Prior authorization	Remains Tier 2

3. DRUGS REMOVED FROM THE FORMULARY

The following brand-name drugs were removed from the formulary because generic is now available and was added to the formulary. Drug removal is effective May 2023.

Brand-name Drug	FDA Indication(s)	Restriction(s)	Alternative(s)
Daliresp	COPD	Quantity limit	roflumilast
Gilenya	Multiple sclerosis	Quantity limit	fingolimod

4. DRUGS REMOVED FROM COVERAGE

The following drugs were excluded from coverage because it is available without a prescription,

effective January 1, 2023:

Drug		
Ivermectin 0.5% lotion	Sklice 0.5% lotion	